Biotechnology

Remiges Ventures Closes Second Fund With $95 Million; Launches RDiscovery Incubator

Remiges Ventures, a US-based cross-border venture capital firm with offices in Seattle, WA and Tokyo, Japan, announced today the final closing of its second fund, Remiges BioPharma Fund II raising a total of$95 million, and the launch of RDiscovery, a new life sciences incubator to nurture and ad...

2021-04-09 00:34 1051

Shanghai Genechem Co., Ltd. (Genechem) Announces appointment of Dr. Eric Rowinsky and Dr. Manuel Hidalgo to Scientific Advisory board, and abstract presentation at AACR 2021 on Claudin 6 Ab and K-Ras TCR-T

SHANGHAI, April 8, 2021 /PRNewswire/ -- Shanghai Genechem Co., Ltd. (Genechem), a discovery company dedicated to novel target discovery and development of novel therapeutics, today announced the appointment of Dr.Eric Rowinsky, President and Executive Chairman of the Board of Rgenix, Inc., and Dr...

2021-04-08 22:00 11891

Antibiotic Alternatives Stimulate New Product Development in Global Animal Feed Ingredient Market

Amino acids dominate the global industry and are expected to generate revenues of$11.5 billion by 2026, says Frost & Sullivan SANTA CLARA, Calif., April 8, 2021 /PRNewswire/ -- Frost & Sullivan's recent analysis finds that the rising demand forhigh-quality meat products across the globe, especia...

2021-04-08 19:03 1074

Inmagene R&D Team expands with two new senior members joining the Company

SAN DIEGO and SHANGHAI and HANGZHOU, China, April 7, 2021 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") today announced that Dr.Anbo Xiang and Dr.Qian Xu joined the company. As CMO (China) and Senior VP, Operations, Dr. Xiang will be responsible for clinical development, operations, an...

2021-04-07 09:00 15555

WuXi Biologics Successfully Completed Pre-License Inspection and Routine GMP Inspection by U.S. FDA

WUXI, China, April 7, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has successfully completed both a Pre-License Inspection (PLI) and a routine GMP inspection by the U.S. FDA (FDA). T...

2021-04-07 08:22 20166

Antengene Announces NMPA Approval of IND Application for ATG-019 in Patients with Advanced Solid Tumors or Non-Hodgkin's Lymphoma

SHANGHAI and HONG KONG, April 6, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncol...

2021-04-06 08:00 6952

Novavax Initiates COVID-19 Vaccine Clinical Trial Crossover

* Crossover allows participants to continue in trials and remain blinded * Ensures that all trial participants receive active vaccine * South Africa and UK crossover arms initiated; US/Mexico PREVENT-19 crossover planned GAITHERSBURG, Md., April 6, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq:...

2021-04-06 05:00 4438

Thailand BOI Okays Biotech Projects Worth 2.4 Bln Baht in Total Investment

BANGKOK, April 5, 2021 /PRNewswire/ -- The Thailand Board of Investment (BOI) said today it has recently approved new projects in the field of advanced biotechnology, worth a combined2.4 billion baht (around USD78 million) in investment, reflecting the increased interest of local and foreign inve...

2021-04-05 23:03 3556

Sophie's Bionutrients Unveils The World's First Plant-Based Burger Patty Made From Microalgae

SINGAPORE, April 1, 2021 /PRNewswire/ -- Sophie's Bionutrients, a next-generation sustainable urban food production technology company, has pushed the frontiers of plant-based food by developing burger patties made from microalgae. S...

2021-04-01 14:25 64731

VISEN's TransCon Human Growth Hormone Phase-III Clinical Trial in China Completes Target Patient Recruitment Number as Scheduled

SHANGHAI, March 31, 2021 /PRNewswire/ -- VISEN Pharmaceuticals, a biotech company committed to the treatment of endocrine-related diseases, announced on March 30 that it had successfully completed its recruiting target of 150 subjects for the Phase-III registration clinical trial inChina to evalu...

2021-03-31 23:53 661

Five New 'Key Opinion Leaders' Appointed to Blinkcns Scientific Advisory Board

Dr. Angelo Antonini, Dr. Matteo Bologna, Roy Jones, Dr. Fidias Leon-Sarmiento, and Dr.Fabrizio Stocchi, will help guide company as they advance central nervous system research CHARLESTON, South Carolina, March 31, 2021 /PRNewswire/ -- Blinkcns, Inc, a biotechnology company pioneering blink refle...

2021-03-31 21:00 422

BIOVAXYS files FDA pre-IND meeting request and briefing package for COVID-T

VANCOUVER, BC, March 31, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTC:LMNGF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancer applications, announced today that it is has filed a pre-IND (Investigational New Drug) meeting request ...

2021-03-31 20:00 1073

Evive Biotech Submits Biologics License Application to US FDA for Ryzneuta(TM)

* BLA submission to the U.S. FDA follows successful conclusion of Evive's Global Phase III Clinical Trial for chemotherapy-induced neutropenia in breast cancer patients. * Evive is the first Chinese biologics company to advance a novel biologic product from pre-clinical studies to a complet...

2021-03-31 11:26 1255

Menarini Silicon Biosystems launches CELLSEARCH® Circulating Multiple Myeloma Cells Assay, a new non-invasive test to monitor disease status in clinical research studies

BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., March 31, 2021 /PRNewswire/ -- Menarini Silicon Biosystems, a pioneer of liquid biopsy and single cell technologies, announced today the launch of a new assay to meet the needs of pharma companies, CROs, clinicians and research scientists working on mult...

2021-03-31 10:00 3023

Innovent Announces Parsaclisib (IBI376) was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Follicular Lymphoma

SAN FRANCISCO and SUZHOU, China, March 31, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...

2021-03-31 08:00 2234

Viva Biotech Announced 2020 Annual Results

The Group's Revenue Surged by 115.7% YoY Revenue from the CFS Business Increased Significantly by 146.3% YoY Establish One-stop Service Platform for Novel Drug Discovery and Production via Internal Growth and External Expansion Financial Highlights of the year ended December 31, 2020: * Reve...

2021-03-31 07:03 2117

European Commission Approves mAbxience's Bevacizumab For The Treatment Of Certain Types Of Cancer

mAbxience, a global fully-fledged biotech company, with over a decade of experience in the development, manufacture and commercialization of biopharmaceuticals, is expanding patient access to biological treatments throughoutEurope. MADRID, March 31, 2021 /PRNewswire/ -- On 31 March 2021, the Eur...

2021-03-31 05:30 9620

Ajinomoto Bio-Pharma Services Expands Manufacturing Agreement with AstraZeneca to Include Drug Product Manufacturing

WETTEREN, Belgium, March 31, 2021 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce a manufacturing agreement expansion with AstraZeneca to include drug product manufact...

2021-03-31 01:04 778

WuXi AppTec Reports Strong 2020 Annual Results

Revenue Up 28.5% Year-over-Year to RMB16,535 Million Net Profit Attributable to Owners of the Company Up 59.6% Year-over-Year to RMB2,960 Million Diluted EPS Up 56.3% Year-over-Year to RMB1.25 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 48.1% Year-over-Year toRMB3,565 Mil...

2021-03-30 21:10 1169

Innovent Announced Financial Results for Full Year Ended December 31, 2020 and Corporate Progress

SAN FRANCISCO and SUZHOU, China, March 30, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...

2021-03-30 20:52 1748
1234567 ... 92